Making up lost ground | Calamatta Cuschieri

U.S. markets come back swinging & busy times ahead for acquisitions

U.S. markets closed sharply higher on Monday whilst European stocks closed lower
U.S. markets closed sharply higher on Monday whilst European stocks closed lower

U.S. markets closed sharply higher on Monday, with major indexes recording their largest one-day percentage gains since the summer of 2015 and recouping nearly half of their losses from last week. The Dow Jones Industrial Average climbed 669.40 points, or 2.8%, to 24,202.60, for its third-best single point gain in history, led by stellar performance for Microsoft Corp, Intel Corp and Apple Inc as the technology sector experienced a strong rebound.

European stocks meanwhile closed lower Monday, as a surging euro squashed an early rally that had been sparked by a loosening in recent trade-related tensions thanks to reports that Washington and Beijing are talking behind the scenes to avoid a trade war. The Stoxx Europe 600 index gave up 0.7% to end at 363.19 and the DAX 30 dropped 0.8% to close at 11,787.26. The FTSE 100 index slid 0.5% to end at 6,888.69 in London.

GlaxoSmithKline – Novartis stake acquisition

GlaxoSmithKline Plc agreed to buy out Novartis AG’s stake in their consumer-health joint venture for $13 billion, days after abandoning its pursuit of a similar unit put on the block by Pfizer Inc. The sale of the 36.5 percent stake in the venture, which was formed in 2015, should close in the second quarter, Basel, Switzerland-based Novartis said Tuesday in a statement. The sale will also strengthen Novartis’s ability to drive shareholder returns and make bolt-on acquisitions, said Novartis CEO, Vas Narasimhan.

The transaction gives Glaxo full control of a business that sells Theraflu cold medicine and Panadol pain relievers while arming Novartis with more firepower for its pharmaceutical operations and acquisitions. It’s the first big strategic move for new chief executive officers at two of Europe’s largest drug companies. Glaxo shares rose as much as 2.8 percent early Tuesday in London, while Novartis rose as much as 2 percent in Zurich.

Carlyle Group acquires Akzo Nobel unit

In another deal, Akzo Nobel has agreed to sell its specialty chemicals business to investors led by U.S. private equity firm Carlyle Group for 10.1 billion euros including debt — a milestone for the Dutch company as it struggles to recover from a tempestuous 2017. Akzo Nobel CEO Thierry Vanlancker, who took charge last July after the bid battle, said he expects 7.5 billion euros in net proceeds from the sale, and vowed to return the “vast majority” to shareholders.

The sale to Carlyle and Singapore’s GIC sovereign wealth fund for a slightly better than expected price will allow Akzo to focus on its main paints and coatings business may also help to repair strained relationships with shareholders unhappy with the rejection of the bid. The deal delivers one of the biggest commitments made by Akzo Nobel in its defense against a 26 billion euro takeover offer from rival PPG Industries last year. Shares rose 3.8 percent to 77.96 euros by 07:45 GMT.

Disclaimer:

This article was issued by Peter Petrov, Trader at Calamatta Cuschieri. For more information visit, www.cc.com.mt. The information, view and opinions provided in this article is being provided solely for educational and informational purposes and should not be construed as investment advice, advice concerning particular investments or investment decisions, or tax or legal advice. Calamatta Cuschieri Investment Services Ltd has not verified and consequently neither warrants the accuracy nor the veracity of any information, views or opinions appearing on this website.

More in Business Comment
Mythoi of a flourishing start-up hub
Business Comment
George M. Mangion
Brexit - is it worth it? | Calamatta Cuschieri
Business Comment
Calamatta Cuschieri
Apple dents markets | Calamatta Cuschieri
Business Comment
Calamatta Cuschieri
U.S. oil prices continue record skid | Calamatta Cuschieri
Business Comment
Calamatta Cuschieri

Get access to the real stories first with the digital edition

Subscribe